MediWound Ltd.
MediWound develops bio-therapeutic solutions for tissue repair and regeneration. They market NexoBrid for removing dead tissue from burn victims. EscharEx has completed Phase II trials for chronic wound debridement. MW005 is in Phase I/II for treating low-risk basal cell carcinoma. The company was incorporated in 2000 and is headquartered in Israel.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.2 |